1 Wall Street Analyst Thinks AbbVie Stock Is Going to $200. Is It a Buy at Around $165?
Wall Street is feeling pretty good about 's (NYSE: ABBV) performance in 2024 so far.
Louise Chen from Cantor Fitzgerald recently initiated coverage on the stock with an overweight rating. Chen also slapped a $200 price target on the pharma stock, which implies a gain of more than 20% from recent prices.
The positive rating is more than a little surprising because AbbVie's lead drug, Humira, lost its market exclusivity in the U.S. last year.
Source Fool.com
AbbVie Inc. Stock
€170.06
-0.290%
With 32 Buy predictions and not a single Sell prediction AbbVie Inc. is an absolute favorite of our community.
With a target price of 180 € there is a slightly positive potential of 5.84% for AbbVie Inc. compared to the current price of 170.06 €.
